Institutional shares held 257 Million
1.57M calls
730K puts
Total value of holdings $11.3B
$69.4M calls
$32.2M puts
Market Cap $14.2B
321,832,000 Shares Out.
Institutional ownership 79.76%
# of Institutions 624


Latest Institutional Activity in EXEL

Top Purchases

Q2 2025
Livforsakringsbolaget Skandia, Omsesidigt Shares Held: 111K ($4.9M)
Q2 2025
Exchange Traded Concepts, LLC Shares Held: 132K ($5.82M)
Q2 2025
Lifestyle Asset Management, Inc. Shares Held: 32.3K ($1.42M)
Q2 2025
Financiere Des Professionnels Fonds D,Investissement Inc. Shares Held: 20.7K ($910K)
Q2 2025
Krilogy Financial LLC Shares Held: 10.3K ($456K)

Top Sells

Q2 2025
Swedbank Ab Shares Held: 842K ($37.1M)
Q2 2025
Lingohr & Partner Asset Management Gmb H Shares Held: 20.9K ($921K)
Q2 2025
Post Resch Tallon Group Inc. Shares Held: 72.8K ($3.21M)
Q2 2025
Pallas Capital Advisors LLC Shares Held: 44.8K ($1.98M)
Q2 2025
North Crest Asset Manangement, LLC Shares Held: 20.4K ($899K)

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.


Insider Transactions at EXEL

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
5.27M Shares
From 30 Insiders
Grant, award, or other acquisition 2.85M shares
Exercise of conversion of derivative security 1.96M shares
Bona fide gift 462K shares
Sell / Disposition
3.68M Shares
From 23 Insiders
Open market or private sale 1.5M shares
Payment of exercise price or tax liability 1.65M shares
Bona fide gift 523K shares
Other acquisition or disposition 4.68K shares

Track Institutional and Insider Activities on EXEL

Follow EXELIXIS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EXEL shares.

Notify only if

Insider Trading

Get notified when an Exelixis, Inc. insider buys or sells EXEL shares.

Notify only if

News

Receive news related to EXELIXIS, INC.

Track Activities on EXEL